Thermo Fisher Scientific announced an agreement to acquire Solventum Corporation’s purification and filtration business for approximately $4.1 billion in cash. The acquisition is expected to be completed by the end of 2025, subject to customary closing conditions and regulatory approvals.

The deal aligns with Thermo Fisher’s strategy to enhance its bioprocessing portfolio by integrating Solventum’s purification and filtration technologies. The company anticipates that the acquisition will strengthen its capabilities in supporting biologics production and improve its market position in the growing life sciences sector.

source: Thermo Fisher Scientific, February 25, 2025.